Wilson's disease (WD) is a life-threatening inborn error of copper metabolism leading to an excessive copper accumulation, mainly in the liver or brain, causing hepatic and neurologic severe symptoms. MedDRA version: 20.0 Level: LLT Classification code 10047988 Term: Wilson's disease System Organ Class: 100000004850
Conditions
Interventions
Trade Name: Cuprior 150 mg film-coated tablets
Product Name: TETA 4HCl
Product Code: TETA 4HCl
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Trientine tetrahydrochloride
CAS Number: 496
Sponsors
Orphalan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient is able to provide and has provided written informed consent has been obtained 2. Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable, including for EU sites, Data Protection Consent 3. Male or female, aged = 18 and = 75 years old at time of consent 4. Patient has a diagnosis of Wilson’s disease, as defined by a prior or current Leipzig score of = 4 5. Patient’s Wilson’s disease is clinically stable, in the opinion of the investigator, and being treated with penicillamine for at least 1 year (52 weeks) prior to the screening/enrolment visit 6. Patient is on a stable dose and regimen of penicillamine for at least 4 months (16 weeks) prior to the screening/enrolment visit (other prescribed treatments for Wilson’s disease not permitted during this period) 7. No anticipated need that patient will require additional pharmacological therapies other than study medication, including prescribed zinc therapy, for the management of copper levels during the study 8. Patient must be willing to maintain stable diet throughout the study, and avoid foods with high copper content, including the Penicillamine Baseline period 9. Patient considered suitable to receive therapy with both TETA 4HCl and penicillamine administered twice a day 10. Negative central laboratory tests for HIV and viral hepatitis (results will be available after start of run-in period) 11. For female patients of childbearing potential, negative urine pregnancy test (at screening/enrolment visit and prior to randomization) 12. For females of childbearing potential, use of a reliable form of contraceptive 13. Patient is considered as able to complete study requirements and attend the study visits, in he opinion of the investigator The Clinical Adjudication Committee will be responsible for reviewing clinical study data provided by the sites to confirm that the penicillamine-treated Wilson’s disease patients enrolled into the Penicillamine Baseline Period are well-controlled, clinically stable, and are suitable for randomisation into the study at Week 12 visit. Information associated with the Inclusion and Exclusion criteria demonstrating that patients are adequately controlled and tolerating penicillamine defined by serum NCC, 24-hour urinary copper excretion, ALT and any other laboratory or clinical findings per protocol will be used for this assessment prior to the Week 12 visit. Patient and site identification will be anonymized to the adjudicators and additionally for the evaluations post-randomisation the adjudicators will be blinded to the treatment allocation. Three adjudication members will review the data independently according to the protocol criteria. A majority assessment of two or more will determine the decision. The recommendation by the Clinical Adjudication Committee on whether or not to include (randomise) the patient will be final. The details of the process and communication with the Investigator will be detailed in a Charter for the Clinical Adjudication Committee Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5
Exclusion criteria
Exclusion criteria: 1. Patient is in ‘de-coppering’ phase of treatment for Wilson’s disease, in the opinion of the investigator 2. Patient evidence of uncontrolled liver disease, including but not limited to: a. Modified Nazer score of > 4 (result may not be available until after start of run-in period on lab results*) b. decompensated cirrhosis c. acute hemolytic anemia d. acute hepatitis e. hepatic malignancy f. evidence of acute liver failure 3. Cause of patient’s liver disease is due to another condition, in the investigator’s opinion 4. Patient has severe anemia defined as hemoglobin of = 9 g/dL (result will be available after start of run-in period*) 5. Patient has experienced a gastrointestinal bleed within 6 months (24 weeks) prior to screening/enrolment visit 6. Patient has moderate or severe renal impairment defined as creatinine clearance of = 30 mL/min (result will may not be available until after start of run-in period*), or patient has nephritis or nephrotic syndrome, in the opinion of the investigator 7. Patient has neurological disease that prevents swallowing of study medication (e.g. requires a nasogastric feeding tube) or requires intensive in-patient medical care 8. Patient is currently taking medication containing trientine for management of Wilson’s disease or has taken it within 4 months (16 weeks) of screening/enrolment visit 9. Patient is currently receiving prescribed zinc therapy for management of Wilson’s disease or has taken it within 4 months (16 weeks) of screening/enrolment visit 10. Patient is taking any of the following concomitant therapies: gold therapy, antimalarial therapy, cytotoxic drugs, oxyphenbutazone, phenyl butazone 11. Patient has a known intolerance, allergy or sensitivity to penicillamine (that is uncontrolled) or to TETA 4HCl, including any component of the study medication 12. For female patients of childbearing potential, planning a pregnancy during study period or currently nursing 13. For female patients of childbearing potential, unable or unwilling to use a reliable form of contraceptive throughout the study 14. Patient is currently participating in another therapeutic study, or has previously participated in a therapeutic study within 30 days of screening/enrolment visit (or longer, if local requirements specify this) 15. Patient has any condition or in any situation which, in the investigator’s opinion, puts the patient at significant risk, could confound study results, or may interfere significantly with the patient’s participation in the study *Samples for screening/enrolment labs can be taken within ± 7 days of visit. In the event that lab value is above the specified threshold, it can be repeated including at the Week 4 and Week 8 visits, with the result available prior to randomization at Week 12.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the efficacy of TETA 4HCl compared to penicillamine. ;Secondary Objective: The safety of TETA 4HCl compared to penicillamine will also be evaluated.;Primary end point(s): The primary endpoint variable of this study will be the absolute value of serum NCC, measured at Screening/enrolment, Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36. ;Timepoint(s) of evaluation of this end point: Measured at Screening/Enrolment, Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): The secondary efficacy measures are: • 24-hour urinary copper excretion • Clinical stability assessment by independent Adjudication Committee • CGIC score Other efficacy measures are: • Unified Wilson’s Disease Rating Scale (UWDRS), neurological scale • Serum total copper and serum ceruloplasmin Significance tests will be performed at the a = 0.05 significance level for two-tailed tests and at a = 0.025 for one-tailed tests. Safety measures: • Adverse events and serious adverse events o Clinically significant laboratory abnormalities and significant changes in neurological signs/symptoms will be reported as AEs • Hematology, biochemistry and coagulation analysis • Urinalysis • Neurological signs and symptoms (using the relevant UWDRS items) • Cognitive assessment using the semantic verbal fluency test • Modified Nazer score • Vital signs (heart rate, blood pressure, respiration rate, body temperature) • Urine pregnancy test (for females of childbearing potential) Pharmacokinetic measures: Plasma samples for subsequent pharmacokinetic (PK) evaluation will be collected at steady state. This will be done at designated sites for patients who received TETA 4HCl. The aim is to collect 2 separate samples (one at Week 24 and one at Week 36) from each patient that represents trough values at steady state. Therefore, the sample should be taken just prior to the patient’s next dose of study drug i.e. before the morning dose or before the evening dose Details for the collection and storage of the PK samples is included in the Laboratory Manual. The following plasma concentrations will be assessed: • The parent compound, trientine • The two metabolites, N1-acetyltriethylenetetramine (MAT) and N1, N10-diacetyltriethylenetetramine (DAT). The outcome of the adjudication will state whether patients are well controlled and clinically stable. The proportion of clinically stable patients at Week 36 and at Week 60 will be computed and reported with | — |
Countries
Austria, Belgium, Brazil, Denmark, France, Germany, Italy, Poland, Sweden, United Kingdom, United States
Contacts
Public ContactClinical Trials Information
Orphalan
Outcome results
None listed